Is Eli Lilly Stock a Buy? [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
associated with weight-loss drugs, it's not the only drug in this category doing well. While Elon Musk recently showed off his slimmed-down figure in a Santa Claus suit on X calling himself "Ozempic Santa," he wasn't taking Ozempic. Reports indicate he was actually taking Eli Lilly 's (NYSE: LLY) weight-loss drug Mounjaro. Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. The stock is up about 36% year to date as of this writing and has gained around 506% over the past five years. Given the stock's strong performance, the natural question becomes whether the stock is still a buy going forward. Let's see if the momentum can continue. A GLP-1 powerhouse While Ozempic has more brand recognition, Eli Lilly's Mounjaro and Zepbound have proven better clinically at helping patients lose weight. The two Eli Lilly drugs use the same active ingredient -- tirzepatide -- but they are appr
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst [Yahoo! Finance]Yahoo! Finance
- Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them [Yahoo! Finance]Yahoo! Finance
- Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver [Forbes]Forbes
- Lilly's Obesity Drug Zepbound To Be Key Health Cost Driver For 2025 [Forbes]Forbes
- Eli Lilly and Company (NYSE: LLY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- LLY's page on the SEC website